润达医疗(603108) - 2022 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2022 was ¥2,873,136,832.13, representing a year-on-year increase of 19.88%[5] - The net profit attributable to shareholders for Q3 2022 was ¥146,488,295.45, an increase of 23.94% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥141,392,256.12, up 22.58% year-on-year[5] - Total revenue for Q3 2022 reached ¥7,634,104,408.50, an increase from ¥6,639,778,191.14 in Q3 2021, representing a growth of approximately 15%[18] - Net profit for Q3 2022 was ¥507,392,397.50, compared to ¥486,105,408.25 in Q3 2021, reflecting a growth of approximately 4.5%[20] - The total comprehensive income for Q3 2022 was approximately ¥506 million, compared to ¥486 million in Q3 2021, indicating an increase of about 4.1%[22] - The company's total revenue for the first three quarters of 2022 reached ¥2,088,865,691.54, an increase from ¥1,930,527,572.57 in the same period of 2021, representing a growth of approximately 8.2%[32] Earnings Per Share - The basic earnings per share for Q3 2022 was ¥0.25, a 25.00% increase compared to the previous year[7] - The diluted earnings per share for Q3 2022 was ¥0.24, representing a 20.00% increase year-on-year[7] - Basic earnings per share for Q3 2022 were ¥0.53, down from ¥0.56 in Q3 2021, a decrease of approximately 5.4%[22] - Diluted earnings per share for Q3 2022 were ¥0.52, compared to ¥0.54 in Q3 2021, reflecting a decrease of about 3.7%[22] Assets and Liabilities - The total assets at the end of the reporting period were ¥14,084,216,708.28, reflecting a year-on-year increase of 17.21%[7] - The total assets as of Q3 2022 amounted to ¥14,084,216,708.28, an increase from ¥12,016,544,118.64 in the previous year, marking a growth of about 17.2%[18] - Total liabilities for Q3 2022 were ¥9,211,124,617.46, compared to ¥7,624,504,350.09 in Q3 2021, representing an increase of approximately 20.8%[18] - The company's total assets increased to ¥8,028,656,772.64, compared to ¥7,454,188,494.16 in the previous year, reflecting a growth of about 7.7%[28] - The total liabilities rose to ¥5,518,729,565.38, up from ¥4,970,730,933.59, marking an increase of approximately 11%[28] Cash Flow - The cash flow from operating activities for the year-to-date was -¥696,829,903.23, indicating a significant decline of 1,057.63% compared to the previous year[7] - The net cash flow from operating activities for the first three quarters of 2022 was approximately -¥697 million, compared to -¥60 million in the same period of 2021, reflecting a significant decline[24] - The net cash flow from operating activities for Q3 2022 was negative CNY 224.10 million, worsening from negative CNY 88.33 million in Q3 2021, indicating operational challenges[35] - Cash inflow from operating activities for the first nine months of 2022 was CNY 3.01 billion, an increase from CNY 2.68 billion in the same period of 2021, showing growth in operational cash generation[35] - The total cash outflow from operating activities in Q3 2022 was CNY 3.48 billion, compared to CNY 2.84 billion in Q3 2021, highlighting rising operational costs[35] Shareholder Information - The total number of common shareholders at the end of the reporting period is 19,857[11] - The largest shareholder, Hangzhou Gongshu State-owned Investment Holding Group Co., Ltd., holds 116,000,000 shares, accounting for 20.02% of total shares[11] - The total number of shares held by the top ten shareholders includes significant stakes from individuals and investment funds, indicating concentrated ownership[11] - The company is actively managing shareholder relationships, with certain shares pledged or frozen, indicating potential liquidity concerns for some shareholders[11] Operational Challenges - The gross profit margin and net profit margin were affected by the pandemic, leading to a decrease in marginal benefits during the reporting period[8] - The company experienced a 14.98% increase in operating revenue for the year-to-date, totaling ¥7,634,104,408.50, despite challenges from pandemic-related disruptions earlier in the year[8] - The company has expanded its medical testing laboratories in certain regions, which has increased operational expenditures significantly, impacting cash flow[10] - The company reported a decrease in cash inflow from the sale of goods and services, totaling CNY 3.01 billion for the first nine months of 2022, compared to CNY 2.68 billion in the same period of 2021[35] Research and Development - Research and development expenses for Q3 2022 were ¥100,535,291.92, up from ¥82,109,791.21 in Q3 2021, indicating a growth of approximately 22.5%[20] - The company's research and development expenses were reported at ¥120,311,136.63, an increase from ¥110,568,720.55 in the previous year, reflecting a growth of approximately 8.3%[32] Investment and Financing - The company reported an investment income of ¥96,505,152.90 in Q3 2022, down from ¥109,879,044.43 in Q3 2021, reflecting a decrease of about 12.2%[20] - Cash inflow from financing activities in the first three quarters of 2022 was approximately ¥6.96 billion, compared to ¥4.93 billion in the same period of 2021, representing an increase of about 41.3%[26] - The company received CNY 3.07 billion from borrowings in Q3 2022, compared to CNY 2.53 billion in Q3 2021, indicating increased reliance on debt financing[35]